Who
Karen Akinsanya
Officer
Company insider
Files Form 4 as: President of R&D, Therapeutics, Schrodinger; Director, Nautilus Biotechnology.
In numbers
- Trades disclosed
- 87
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $8.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 10 Feb 2020
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code M | $137K31,599 at $4.34 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $280K10,000 at $28.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $648K21,599 at $30.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code M | —31,599 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code M | —31,599 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code M | $137K31,599 at $4.34 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $280K10,000 at $28.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $648K21,599 at $30.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NAUT Nautilus Biotechnologyoption or derivative · Life-science tools | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $18K1,366 at $12.90 | filing |
| 5 Mar 2026filed 6 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $18K1,366 at $12.90 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —6,077 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —27,576 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —48,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Sold | $26K2,206 at $11.99 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —48,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —24,250 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —6,077 at $0.00 | filing |
News
Claritev (NYSE:CTEV) and Schrodinger (NASDAQ:SDGR) Financial SurveySDGR · dailypolitical.com · 19 Oct 2026Head to Head Review: Schrodinger (NASDAQ:SDGR) versus VSee Health (NASDAQ:VSEE)SDGR · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Karen Akinsanya; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.